Xbrane Biopharma AB (XBRANE) — Tangible Net Worth Ratio
Xbrane Biopharma AB (XBRANE) has a Tangible Net Worth Ratio of 47.1% as of December 2025. This metric is calculated by deducting intangible assets (Skr296.46 Million) from net assets (Skr560.65 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See XBRANE working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Xbrane Biopharma AB Tangible Net Worth Ratio (2012–2025)
This chart shows how Xbrane Biopharma AB's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 47.1%, reflecting net assets of Skr560.65 Million with intangible assets of Skr296.46 Million SEK. See XBRANE cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Xbrane Biopharma AB stock valuation.
| Year | Tangible NW Ratio | Net Assets (SEK) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 47.1% | Skr560.65 Million | Skr296.46 Million | Skr671.62 Million | ▲ +27.5 pp |
| 2024 | 19.6% | Skr208.54 Million | Skr167.69 Million | Skr842.43 Million | ▼ -22.2 pp |
| 2023 | 41.8% | Skr171.34 Million | Skr99.67 Million | Skr653.51 Million | ▼ -34.2 pp |
| 2022 | 76.0% | Skr424.89 Million | Skr102.00 Million | Skr690.51 Million | ▼ -12.5 pp |
| 2021 | 88.5% | Skr431.74 Million | Skr49.67 Million | Skr688.43 Million | ▼ -9.9 pp |
| 2020 | 98.4% | Skr257.71 Million | Skr4.08 Million | Skr463.76 Million | ▲ +1.2 pp |
| 2019 | 97.3% | Skr184.32 Million | Skr5.05 Million | Skr338.94 Million | ▲ +4.2 pp |
| 2018 | 93.1% | Skr83.07 Million | Skr5.77 Million | Skr252.88 Million | ▲ +0.2 pp |
| 2017 | 92.9% | Skr88.41 Million | Skr6.30 Million | Skr110.96 Million | ▲ +0.8 pp |
| 2016 | 92.1% | Skr107.30 Million | Skr8.46 Million | Skr118.11 Million | ▲ +4.8 pp |
| 2015 | 87.3% | Skr47.51 Million | Skr6.03 Million | Skr75.33 Million | ▼ -12.7 pp |
| 2014 | 100.0% | Skr6.30 Million | Skr0.00 | Skr6.69 Million | ▲ +0.0 pp |
| 2013 | 100.0% | Skr8.69 Million | Skr0.00 | Skr9.20 Million | ▲ +0.0 pp |
| 2012 | 100.0% | Skr88.11K | Skr0.00 | Skr657.01K | — |